DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Megace (Megestrol) - Uterine Leiomyoma - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Uterine Leiomyoma (4)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Megace (Megestrol) where reactions include uterine leiomyoma. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Megace side effects in 56 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-08

Patient: 56 year old female, weighing 83.8 kg (184.3 pounds)

Reactions: Anaemia, Uterine Leiomyoma, Gastrooesophageal Reflux Disease, Decreased Appetite, Hypokalaemia, Vaginal Haemorrhage

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Metoprolol Tartrate
    Dosage: 25 mg (25 mg, 1 in 1 d), oral
    Administration route: Oral
    Indication: Hypertension
    Start date: 2011-09-16

Axitinib (Axitinib)
    Dosage: 10 mg (5 mg, 2 in 1 d), oral; 6 mg (3 mg, 2 in 1 d), oral
    Administration route: Oral
    Indication: Metastatic Malignant Melanoma
    Start date: 2011-06-28

Axitinib (Axitinib)
    Dosage: 10 mg (5 mg, 2 in 1 d), oral; 6 mg (3 mg, 2 in 1 d), oral
    Administration route: Oral
    Indication: Metastatic Malignant Melanoma
    Start date: 2011-11-30

Carboplatin
    Dosage: (670 mg), intravenous; 26.9048 mg (565 mg, 1 in 3 wk), intravenous
    Indication: Metastatic Malignant Melanoma
    Start date: 2011-09-22
    End date: 2011-09-22

Carboplatin
    Dosage: (670 mg), intravenous; 26.9048 mg (565 mg, 1 in 3 wk), intravenous
    Indication: Metastatic Malignant Melanoma
    Start date: 2011-10-20
    End date: 2011-10-20

Paclitaxel
    Dosage: (300 mg), intravenous; 10.2381 mg (215 mg, 1 in 3 wk), intravenous
    Indication: Metastatic Malignant Melanoma
    Start date: 2011-09-22
    End date: 2011-09-22

Paclitaxel
    Dosage: (300 mg), intravenous; 10.2381 mg (215 mg, 1 in 3 wk), intravenous
    Indication: Metastatic Malignant Melanoma
    Start date: 2011-10-20
    End date: 2011-10-20

Prempro
    Dosage: 0.625mg/2.5mg (1 in 1 d), oral;
    Administration route: Oral
    Indication: Arthritis
    Start date: 2007-01-01

Celecoxib
    Dosage: 200 mg (200 mg, 1 in 1 d), oral; 200 mg (200 mg, 1 in 1 d), oral
    Administration route: Oral
    Indication: Arthritis
    Start date: 2007-01-01
    End date: 2011-11-01

Megace
    Dosage: 5 cc (5, 1 in 1 d), oral; 5 cc (5, 1 in 1 d), oral
    Administration route: Oral
    Indication: Decreased Appetite
    Start date: 2011-09-27

Megace
    Dosage: 5 cc (5, 1 in 1 d), oral; 5 cc (5, 1 in 1 d), oral
    Administration route: Oral
    Indication: Decreased Appetite
    Start date: 2011-11-28

Other drugs received by patient: Benadryl; MS Contin; Zofran; Wellbutrin



Possible Megace side effects in 56 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-16

Patient: 56 year old female, weighing 83.8 kg (184.3 pounds)

Reactions: Uterine Leiomyoma, Haemorrhagic Anaemia, Gastrooesophageal Reflux Disease, Hypokalaemia, Vaginal Haemorrhage

Drug(s) suspected as cause:
Megace
    Dosage: 5 cc (5,4 in 1 d), oral
    Administration route: Oral
    Indication: Decreased Appetite
    Start date: 2011-11-28

Megace
    Dosage: 5 cc (5,4 in 1 d), oral
    Administration route: Oral
    Indication: Decreased Appetite
    Start date: 2011-09-27

Celecoxib
    Dosage: 200 mg (200 mg, 1 in 1 d), oral
    Administration route: Oral
    Indication: Arthritis
    Start date: 2007-01-01
    End date: 2011-11-01

Paclitaxel
    Dosage: 10.2381 mg (215 mg, 1 in 3 wk), intravenous
    Indication: Metastatic Malignant Melanoma
    Start date: 2011-10-20
    End date: 2011-10-20

Metoprolol Tartrate
    Dosage: 25 mg (25 mg, 1 in 1 d), oral
    Administration route: Oral
    Indication: Hypertension
    Start date: 2011-09-16

Carboplatin
    Dosage: 26.9048 mg (565 mg, 1 in 3 wk), intravenous
    Indication: Metastatic Malignant Melanoma
    Start date: 2011-10-20
    End date: 2011-10-20

Prempro
    Dosage: 0.625mg/2.5mg (1 in 1 d), oral
    Administration route: Oral
    Indication: Arthritis
    Start date: 2007-01-01

Axitinib (Axitinib)
    Dosage: 2 dosage forms (1 dosage forms, 2 in 1 d), oral
    Administration route: Oral
    Indication: Metastatic Malignant Melanoma
    Start date: 2011-11-30

Other drugs received by patient: Wellbutrin (Bupropion0; Benadryl; Zofran; MS Contin



Possible Megace side effects in 56 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-07

Patient: 56 year old female, weighing 83.8 kg (184.3 pounds)

Reactions: Uterine Leiomyoma, Haemorrhagic Anaemia, Gastrooesophageal Reflux Disease, Decreased Appetite, Vaginal Haemorrhage, Hypokalaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Axitinb (Axitinib)
    Dosage: 2 dosage forms (1 dosage forms,2 in 1 d),oral ; 6 mg (3 mg,2 in 1 d),oral
    Administration route: Oral
    Indication: Metastatic Malignant Melanoma
    Start date: 2011-06-28

Axitinb (Axitinib)
    Dosage: 2 dosage forms (1 dosage forms,2 in 1 d),oral ; 6 mg (3 mg,2 in 1 d),oral
    Administration route: Oral
    Indication: Metastatic Malignant Melanoma
    Start date: 2011-11-30

Carboplatin
    Dosage: 26.9048 mg (565 mg,1 in 3 wk),intravenous
    Indication: Metastatic Malignant Melanoma
    Start date: 2011-10-20
    End date: 2011-10-20

Megace
    Dosage: 5 cc (5, 4 in 1 d),oral
    Administration route: Oral
    Indication: Decreased Appetite
    Start date: 2011-09-27

Metoprolol Tartrate
    Dosage: 25 mg (25 mg,1 in 1 d),oral
    Administration route: Oral
    Indication: Hypertension
    Start date: 2011-09-16

Celecoxib
    Dosage: 200 mg (200 mg,1 in 1 d),oral ; 200 mg (200 mg,1 in 1 d),oral
    Administration route: Oral
    Indication: Arthritis
    Start date: 2007-01-01
    End date: 2011-11-01

Prempro
    Dosage: 0.625mg/2.5mg (1 in 1 d),oral
    Administration route: Oral
    Indication: Arthritis
    Start date: 2007-01-01

Paclitaxel
    Dosage: 10.2381 mg (215 mg,1 in 3 wk),intravenous
    Indication: Metastatic Malignant Melanoma
    Start date: 2011-10-20
    End date: 2011-10-20

Other drugs received by patient: Benadryl; MS Contin; Wellbutrin; Zofran



Possible Megace side effects in 56 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-02-24

Patient: 56 year old female, weighing 65.9 kg (145.0 pounds)

Reactions: Uterine Leiomyoma, Anaemia, Gastrooesophageal Reflux Disease, Hypokalaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Metoprolol Tartrate
    Dosage: 25 mg (25 mg, 1 in 1 d), oral
    Administration route: Oral
    Indication: Hypertension
    Start date: 2011-09-16

Axitinib (Axitinib)
    Dosage: 2 dosage forms (1 dosage forms, 2 in 1 d), oral
    Administration route: Oral
    Indication: Metastatic Malignant Melanoma
    Start date: 2011-11-30

Celebrix (Celecoxib)
    Dosage: 200 mg (200 mg, 1 in 1 d), oral
    Administration route: Oral
    Indication: Menopause
    Start date: 1997-01-01
    End date: 2011-11-01

Prempro
    Dosage: 0.625 mg/2.5 mg (1 in 1 d), oral
    Administration route: Oral
    Indication: Arthritis
    Start date: 2007-01-01

Carboplatin
    Dosage: 26.9048 mg (565 mg, 1 in 3 wk), intravenous
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-10-20
    End date: 2011-10-20

Paclitaxel
    Dosage: 10.2381 mg (215 mg, 1 in 3 wk), intravenous
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-10-20
    End date: 2011-10-20

Megace
    Dosage: 5 cc (1 in 1 d), oral
    Administration route: Oral
    Indication: Decreased Appetite
    Start date: 2011-09-27

Other drugs received by patient: Benadryl; Wellbutrin; Zofran; MS Contin; Megace; Celebrex

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017